{"id":5333,"date":"2014-11-20T13:32:32","date_gmt":"2014-11-20T12:32:32","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=5333"},"modified":"2014-11-20T19:19:10","modified_gmt":"2014-11-20T18:19:10","slug":"ims-spesa-farmaceutica-30-entro-2018","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ims-spesa-farmaceutica-30-entro-2018\/","title":{"rendered":"Ims: pharmaceutical spending +30% by 2018"},"content":{"rendered":"<p><i>Here are the forecasts of the Institute for healthcare informatics for the next few years<\/i><\/p>\n<p><a href=\"http:\/\/www.aboutpharma.com\/news\/farmaco\/ims-spesa-farmaceutica-30-entro-il-2018\/\" target=\"_blank\" rel=\"noopener\">Thursday 20 November 2014 by Redazione AboutPharma and Medical Devices<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" alt=\"The Global Use of Medicines:&lt;br&gt; Outlook through 2017\" src=\"http:\/\/www.imshealth.com\/deployedfiles\/imshealth\/Global\/Content\/Corporate\/IMS%20Health%20Institute\/Reports\/Global_Use_of_Meds_Outlook_2017\/Global_Use_Of_Meds.png\" width=\"191\" height=\"235\" \/>World pharmaceutical spending will increase by up to 30% over the period\u00a0<b>2013-2018<\/b>, reaching nearly $1.3 trillion. And the <a href=\"http:\/\/www.imshealth.com\/portal\/site\/imshealth\/menuitem.762a961826aad98f53c753c71ad8c22a\/?vgnextoid=9f819e464e832410VgnVCM10000076192ca2RCRD&amp;vgnextchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&amp;vgnextfmt=default\" target=\"_blank\" rel=\"noopener\">prediction of<b>Institute for healthcare informatics (Ims)<\/b>.<\/a><\/p>\n<p>The world pharmaceutical market is expected to register a\u00a0<b>compound mean growth rate (Cagr) of 4-7%<\/b>, with an increase of 305-335 billion dollars in the period 2013-2018 compared to 194 billion recorded between 2009 and 2013, when the CAGR stood at 5.2%.<\/p>\n<p>According to Ims, the leap forward will be mainly driven by innovative medicines, better access to treatments and the reduction of the impact of patent expiration. The annual expenditure, then, should record a peak in 2014 a\u00a0<b>70 billion dollars<\/b>, up from 44 billion in 2013 and from 26 in 2012. Subsequently, the value will stabilize until 2018, while remaining at levels higher than those observed during 2009-2013.<\/p>\n<p>\u201cThe high level of growth in spending that we expect over the next five years \u2013 he says<b>Murray Aitken, executive director of Ims<\/b>\u00a0\u2013 reflects an unusual combination of higher spending from the surge in innovative medicines, and lower savings from patent expirations. This is particularly evident this year and will be next, especially in the United States, which accounts for more than a third of the global market.\u201d<\/p>\n<p>THE\u00a0<b>more developed markets<\/b>\u00a0(USA, France, Germany, Spain, United Kingdom, Italy and Japan) will be the main drivers of this growth: even if the price increase will be hampered by cost containment measures, volumes will continue to contribute to overall growth. Only France and Spain will see a contraction in per capita pharmaceutical spending in 2018, as a result of national policies.<\/p>\n<p>THE\u00a0<b>21 pharmamerging markets<\/b>, which currently account for 25% of global pharmaceutical expenditure, are projected to grow by more than 50% by 2018, with a Cagr of 8-11% over the forecast period, thanks to expanding access to care due to expanding economies and government efforts to provide universal health coverage. About 200 new drugs are expected to be launched over the next five years.<\/p>","protected":false},"excerpt":{"rendered":"<p>Ecco le previsioni dell&#8217;Institute for healthcare informatics per i prossimi anni gioved\u00ec 20 novembre 2014 di Redazione\u00a0 AboutPharma and Medical Devices La spesa farmaceutica mondiale aumenter\u00e0 fino al 30% nel periodo\u00a02013-2018, raggiungendo quasi 1,3 trilioni di dollari. \u00c8 la previsione dell\u2019Institute for healthcare informatics (Ims). Il mercato farmaceutico mondiale dovrebbe registrare un\u00a0tasso di crescita medio &hellip;<\/p>","protected":false},"author":4,"featured_media":739,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47,26],"class_list":["post-5333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/5333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=5333"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/5333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=5333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=5333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=5333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}